U.S. Advance Auto Parts, Molina Healthcare, Walmart
Aug 16 (Reuters) -Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Advance Auto Parts, Molina Healthcare and Walmart on Friday.
HIGHLIGHTS
* Advance Auto Parts Inc AAP.N: JP Morgan cuts target price to $55 from $68 |
* Dare Bioscience Inc DARE.O: Jonestrading raises target price to $13 from $5 |
* Molina Healthcare Inc MOH.N: Mizuho raises target price to $382 from $350 |
* Roper Technologies Inc ROP.O: Jefferies raises target price to $635 from $625 |
* Walmart WMT.N: RBC raises target price to $80 from $74 |
Following is a summary of research actions on U.S. companies reported by Reuters on Friday. Stock entries are in alphabetical order.
* Advance Auto Parts Inc AAP.N: JP Morgan cuts target price to $55 from $68 |
* AGNC Investment Corp AGNC.O: RBC raises target price to $11 from $10 |
* Alibaba Group BABA.N: JP Morgan raises target price to $108 from $100 |
* Amcor Plc AMCR.N: Baird raises target price to $11 from $10 |
* Amicus Therapeutics Inc FOLD.O: JP Morgan cuts target price to $16 from $17 |
* Applied Materials Inc AMAT.O: JP Morgan raises target price to $250 from $240 |
* Ardent Health Partners Inc ARDT.N: Mizuho raises target price to $21 from $20 |
* BJ's Wholesale Club Holdings Inc BJ.N: JP Morgan raises PT to $76 from $74 |
* Brandywine Realty Trust BDN.N: Evercore ISI raises target price to $5.50 from $5 |
* Centene Corp CNC.N: Mizuho raises target price to $77 from $76 |
* Cheniere Energy Inc LNG.N: RBC raises target price to $201 from $198 |
* Dare Bioscience Inc DARE.O: Jonestrading raises target price to $13 from $5 |
* Deere & Co DE.N: Daiwa Capital Markets cuts target price to $425 from $440 |
* Electra Battery Materials ELBM.O: Alliance Global Partners cuts PT to $1 from $1.5 |
* ESS Tech Inc GWH.N: Canaccord Genuity cuts target price to $1 from $1.25 |
* Globant SA GLOB.N: Piper Sandler raises target price to $240 from $238 |
* Mercury Systems Inc MRCY.O: Jefferies raises target price to $30 from $24 |
* Molina Healthcare Inc MOH.N: Mizuho raises target price to $382 from $350 |
* Optimizerx Corp OPRX.O: RBC cuts target price to $14 from $17 |
* Perspective Therapeutics Inc CATX.A: RBC cuts target price to $27 from $29 |
* Quipt Home Medical Corp QIPT.O: Canaccord Genuity cuts target price to $6 from $8 |
* Root Inc ROOT.O: KBW cuts target price to $82 from $88 |
* Roper Technologies Inc ROP.O: Jefferies raises target price to $635 from $625 |
* Roper Technologies Inc ROP.O: RBC raises target price to $675 from $674 |
* Sphere Entertainment Co SPHR.N: JP Morgan raises target price to $57 from $37 |
* Sphere Entertainment Co SPHR.N: JP Morgan raises to overweight from neutral |
* UnitedHealth UNH.N: Mizuho raises target price to $650 from $560 |
* Upwork Inc UPWK.O: Roth MKM cuts target price to $13 from $19 |
* Viracta Therapeutics VIRX.O: Leerink Partners cuts to market perform from outperform |
* Viracta Therapeutics VIRX.O: Leerink Partners cuts PT to $3 from $5 |
* Vornado Realty Trust VNO.N: Evercore ISI raises target price to $32 from $31 |
* Walmart WMT.N: D.A. Davidson raises target price to $85 from $75 |
* Walmart WMT.N: HSBC raises target price to $85 from $81 |
* Walmart WMT.N: Jefferies raises target price to $85 from $80 |
* Walmart WMT.N: JP Morgan raises target price to $83 from $81 |
* Walmart WMT.N: Piper Sandler raises target price to $83 from $81 |
* Walmart WMT.N: RBC raises target price to $80 from $74 |
* Walmart WMT.N: Roth MKM raises target price to $81 from $71 |
* Walmart WMT.N: TD Cowen raises target price to $85 from $80 |
* Walmart WMT.N: Telsey Advisory Group raises target price to $82 from $75 |
(Compiled by Bengaluru Newsroom)
</body></html>
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
